JMP maintains $78 target on Cytokinetics stock after trial update

On Tuesday, JMP Securities analyst Jason Butler reaffirmed a Market Outperform rating and a $78.00 price target for Cytokinetics stock, traded on (NASDAQ:CYTK). According to InvestingPro data, analyst targets for CYTK range from $47 to $120, with the stock currently trading at $39.81. This endorsement follows the announcement from Bristol-Myers (NYSE:BMY) of unfavorable results from their Phase 3 ODYSSEY-HCM trial of mavacamten for patients with non-obstructive hypertrophic cardiomyopathy (nHCM).

Butler expressed continued confidence in Cytokinetics’ aficamten for nHCM, distinguishing it from mavacamten despite the latter’s recent trial failure. The analyst’s optimism is rooted in the strength of aficamten’s Phase 2 results, its Phase 3 trial design, and its unique product profile. The company has shown strong revenue growth of 145% in the last twelve months, though InvestingPro data indicates it operates with moderate debt levels and maintains healthy liquidity with a current ratio of 6.17.

The analyst highlighted the potential for aficamten, emphasizing that the negative results from Bristol-Myers’ trial are likely specific to mavacamten and not indicative of a class effect. This suggests a distinct physiochemical profile for aficamten that could offer a different therapeutic avenue for nHCM patients. The stock has demonstrated resilience with a 15% return over the past week, despite broader market volatility. Get deeper insights into CYTK’s potential with a comprehensive Pro Research Report, available exclusively on InvestingPro, along with 8 additional key ProTips for informed decision-making.

JMP Securities had the opportunity to speak with Cytokinetics management, who conveyed their continued belief in aficamten’s potential for nHCM patients. The management team confirmed that the Phase 3 ACADIA-HCM trial, which is evaluating aficamten in this patient group, is expected to complete enrollment in the second half of 2025.

Investors are keeping an eye on Cytokinetics as the company progresses with its Phase 3 trial, which could potentially validate the firm’s confidence in aficamten and justify JMP Securities’ maintained stock rating and price target.

In other recent news, Cytokinetics has been the focus of several analyst reports and clinical trial updates. JMP Securities reiterated a Market Outperform rating on Cytokinetics, maintaining a $78 price target, largely driven by optimism surrounding the MAPLE-HCM trial of aficamten, a treatment for hypertrophic cardiomyopathy (HCM). H.C. Wainwright also reaffirmed a Buy rating with a $120 price target, highlighting promising Phase 2 data for another candidate, EDG-7500™, despite differences in trial design compared to aficamten. Cantor Fitzgerald maintained an Overweight rating, emphasizing Afi™ as a leading treatment in its class and pointing to upcoming data from the MAPLE and ACACIA-HCM studies as critical for Cytokinetics’ market position.

Raymond (NSE:RYMD) James supported an Outperform rating with an $81 target, suggesting that uncertainties in Edgewise Therapeutics’ EDG-7500 trial could favor Cytokinetics in the competitive landscape of cardiac myosin inhibitors. The analyst reports reflect a consensus on the potential impact of Cytokinetics’ ongoing trials and commercial strategies. The anticipation of trial results, particularly for aficamten, is expected to influence the company’s market dynamics significantly. The emphasis on robust clinical data and strategic commercial approaches underscores the company’s focus on expanding its treatment options for cardiomyopathy. These developments continue to shape investor perspectives on Cytokinetics’ future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.